Artificial intelligence in cardiovascular imaging: risks, mitigations and the path to safe implementation bit.ly/4rp7LPR

Predicting cardiovascular events from routine mammograms using machine learning bit.ly/4d6EZ2L

Want to stay informed about the latest news and events at CRY? Subscribe to our monthly e-newsletter for all the latest updates. Sign up here: c-r-y.org.uk/subscribe/

New AI heart failure screening tool could save lives, cut hospital waiting lists and deliver major NHS cost savings, via @EurekAlert! @QMUL eurekalert.org/news-releases…

What does the scientific evidence show? 🔸Multiple large studies, including INTERHEART, UK Biobank analyses and other prospective cohorts, suggest that ApoB predicts cardiovascular events at least as well as and often better than LDL-C. ✅ApoB the best single blood marker of atherogenic particle burden. 6/n

🚨 Raising your HDL does not protect your heart. Every major trial that tried to increase HDL cholesterol failed to reduce heart attacks or cardiovascular death. But the data says otherwise than what your doctor may have told you for the last 30 years. I am a cardiologist. I have seen patients handed a number and told they were protected. They were not. 💓 Here is what the science actually says. The HDL hypothesis made biological sense. HDL removes cholesterol from arterial walls and shuttles it back to the liver. That process is called reverse cholesterol transport. It sounded like the perfect defense against atherosclerosis. So we built drugs to raise it. Three separate drug classes. All of them failed. 🔬 The trials told us everything we needed to know. ✅ AIM-HIGH (niacin): Raised HDL by 25%. Zero reduction in cardiovascular events. Trial stopped early for futility. ✅ HPS2-THRIVE (niacin laropiprant): 58,000 patient-years of follow-up. No benefit on major cardiovascular events. Serious adverse events increased. ✅ DAL-OUTCOMES (dalcetrapib): Raised HDL by 31%. No reduction in heart attacks or death. ✅ ILLUMINATE (torcetrapib): Raised HDL by 72%. Cardiovascular deaths actually increased. Trial terminated. ✅ ACCELERATE (evacetrapib): Raised HDL by 130%. Zero reduction in cardiovascular events. That is five trials. Thousands of patients. Billions of dollars. Every single one failed. ⚠️ The mechanism alone was never the point. Causality is the point. HDL is a marker. It correlates with cardiovascular risk in observational data because low HDL often travels with high triglycerides, insulin resistance, visceral fat, and elevated ApoB. When you fix the underlying metabolic dysfunction, HDL rises as a passenger. It is not the driver. Mendelian randomization studies confirmed this. Genetic variants that raise HDL naturally do not reduce cardiovascular disease risk. That is the cleanest evidence we have. The gene does not care about your doctor's optimism. 🩺 The real driver of atherosclerosis is ApoB. ApoB is the protein on every atherogenic particle. LDL, VLDL, IDL, Lp(a). Each one carries exactly one ApoB molecule. ApoB directly measures how many particles are trafficking cholesterol into your arterial wall. Lowering ApoB works. Every trial that has ever reduced ApoB has reduced cardiovascular events. Raising HDL does not. ❤️ Bottom line: HDL is not protective. It is a bystander with a good reputation. Decades of clinical trials have proven that raising it does nothing to your event rate. Get your ApoB measured. Get your Lp(a) measured. Know your particle count. A patient who focuses on ApoB reduction through lifestyle, statins, and when appropriate PCSK9 inhibitors, can cut their cardiovascular event risk by 50% or more over a decade. That is the difference between a heart attack at 58 and living to watch your grandchildren grow up. The question is no longer what is your HDL. The question is what is your ApoB. #Cardiology #HeartDisease #HeartHealth #CardiovascularHealth #HDL #ApoB #CholesterolMyths #LDL #PreventiveCardiology #MetabolicHealth

For medical information, general AI frontier models (Google, OpenAI, Anthropic) outperformed specialized @EvidenceOpen and @UpToDate as assessed by 12 US clinicians, randomized and blinded to which model and extensive testing/benchmarks. This was not anticipated. @NatureMedicine nature.com/articles/s41591-0…

Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy newsroom.clevelandclinic.org…

194 people were screened on 16 and 17 of May at Bishopton Sports & Social Club. This screening event was held in memory of Matthew Seymour and also marked the 1,000th person screened in his memory. Thank you to everyone involved. #testmyheart

Types of ventricular tachycardia

Ruislip couple fund screening day in memory of tragic son hillingdontimes.co.uk/news/2…

My 15-Year-Old Son Collapsed During A Basketball Game. The 1 Thing That Could Have Saved Him Was Nowhere To Be Found yahoo.com/news/us/articles/1…

Cardiac screening programme started in memory of Rugby man to return this month rugbyobserver.co.uk/news/car…

Delighted to share that the third edition of Emergencies in Cardiology is being released in September. Fully revised and updated to reflect the latest investigations, therapies and international guidelines, it keeps the format that's made it a trusted companion for front-line emergency, medical and cardiac teams: concise, bullet-point, and uniquely structured so you can find what you need by problem or by diagnosis. Whether that's timing a temporary pacing wire, managing cardiogenic shock, a pre-operative assessment, or reading a difficult ECG. It has been a privilege to work on this edition with Robin Choudhury and Tom Cahill along with the fantastic support from @OUPAcademic For colleagues and trainees across cardiology, emergency and acute medicine - I do hope it earns a place in your pocket. amazon.co.uk/Emergencies-Car… #Cardiology #AcuteMedicine #MedicalEducation #CardiovascularMedicine #FOAMed #EmergenciesInCardiology #OxfordUniversityPress

Millions live with undiagnosed heart rhythm disorders – World Heart Rhythm Week 2026 calls for urgent action news-medical.net/news/202606…

97 people were screened on 19th of May at The British Racing School @BRSNewmarket in #Newmarket This screening was in memory of Amelia Melanie Osborne. Thank you to all involved. #testmyheart.

Surge in silent killer heart condition in young women - 5 signs you're at risk thesun.co.uk/health/39273089…

“Is a Coronary #CalciumScore of 0 enough to reassure patients on their low CV risk?” Dr Nik Sabharwal, Consultant Cardiologist at @OUHospitals, shared an excellent presentation highlighting how Caristo’s FAI-Score™ technology is advancing coronary artery disease management by quantifying hidden coronary inflammation on cardiac CT. He shared vital updates on clinical management and real-world progress from our ongoing NHS pilot, which is helping clinicians at Rapid Access Chest Pain Clinics better risk-stratify patients and optimize treatment management. It was great to see the critical topic of coronary inflammation take centre stage at the @BritishCardioSo annual conference in Manchester this week! What a fantastic turnout at #BCS2025! 👇 💡 Learn more about FAI-Score at caristo.com

Cardiac telerehabilitation 📱 provides improvements in cardio-respiratory fitness and functional capacity with no statistically significant difference compared with center-based cardiac rehabilitation 👉 doi.org/10.1093/eurjpc/zwag2…

This #WHRW2026 we are shining a spotlight on the range of treatment options available for those living with arrhythmias. While many people are familiar with traditional ICDs, fewer are aware of newer device therapies such as the EV-ICD: loom.ly/qsnYEis